REGENERON PHARMACEUTICALS (RGO.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:RGO - US75886F1075 - Common Stock
RGO.DE Key Statistics, Chart & Performance
The current stock price of RGO.DE is 673.6 EUR.
RGO.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| ARGX.BR | ARGENX SE | 72.78 | 48.17B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.41B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 837.02M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 699.13M | ||
| 6IV.DE | INVENTIVA SA | N/A | 651.37M |
Related stock screener links
About RGO.DE
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,106 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Company Info
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK US
Employees: 15158
Phone: 17813705000
REGENERON PHARMACEUTICALS / RGO.DE FAQ
Can you describe the business of REGENERON PHARMACEUTICALS?
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,106 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
What is the current price of RGO stock?
The current stock price of RGO.DE is 673.6 EUR. The price increased by 0.09% in the last trading session.
What is the dividend status of REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (RGO.DE) has a dividend yield of 0.45%. The yearly dividend amount is currently 0.
What is the ChartMill technical and fundamental rating of RGO stock?
RGO.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (RGO.DE) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of RGO stock?
REGENERON PHARMACEUTICALS (RGO.DE) has a market capitalization of 70.80B EUR. This makes RGO.DE a Large Cap stock.
What is the ownership structure of REGENERON PHARMACEUTICALS (RGO.DE)?
You can find the ownership structure of REGENERON PHARMACEUTICALS (RGO.DE) on the Ownership tab.
RGO.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RGO.DE.
RGO.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RGO.DE. Both the profitability and financial health of RGO.DE have multiple concerns.
RGO.DE Financial Highlights
Over the last trailing twelve months RGO.DE reported a non-GAAP Earnings per Share(EPS) of 38.92. The EPS decreased by -0.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.13% | ||
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| Debt/Equity | 0.09 |
RGO.DE Forecast & Estimates
34 analysts have analysed RGO.DE and the average price target is 669.21 EUR. This implies a price decrease of -0.65% is expected in the next year compared to the current price of 673.6.
For the next year, analysts expect an EPS growth of -6.32% and a revenue growth -0.32% for RGO.DE